Table 1:
Study | Country | N | Ages | Follow-Up Interval (years) | Favorable Outcome Definition | % Favorable Outcome | |
---|---|---|---|---|---|---|---|
Ganesan 2000 | United Kindgom | 90 | 3m-15y | Median | 3 | Composite Score < 4 (“impairments unlikely to interfere with daily life”) | 40% |
Range | 0.25–13 | ||||||
deVeber 2000 | Canada | 123 | 0–17.8y | Mean | 2.07 | PSOM Classification Normal-Mild (Total Score 0–0.5) | 52% |
Range | 0.01–17.59 | ||||||
DeSchryver 2000 | Netherlands | 27 | 3m-14y | Mean | 7.1 | mRS 0–1 | 59% |
Range | 0.25–20 | ||||||
Steinlen 2004 | Switzerland | 16 | 6m-16.2y | Mean | 7 | mRS 0–1 | 56% |
Range | 0.5–16.2 | ||||||
Goeggel-Simonetti 2017 | Switzerland | 95 | 1m-16y | Median | 6.9 | mRS 0–1 | 56% |
IQR | 4.7–9.4 | ||||||
deVeber 2017 | Canada | 667 | 0–18y | Mean | 3 | Clinician Grading: Normal-Mild | 68% |
IQR | 2.8–3.2 |